Wealth Enhancement Advisory Services LLC Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Wealth Enhancement Advisory Services LLC grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 65.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,334 shares of the biopharmaceutical company's stock after purchasing an additional 13,915 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Catalyst Pharmaceuticals were worth $857,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock worth $244,000 after purchasing an additional 580 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after acquiring an additional 875 shares during the period. PDT Partners LLC boosted its stake in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock worth $431,000 after buying an additional 1,030 shares during the period. Finally, Xponance Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 6.8% in the fourth quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company's stock valued at $392,000 after purchasing an additional 1,189 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider owned 41,081 shares of the company's stock, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the transaction, the insider directly owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This represents a 38.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 247,924 shares of company stock valued at $5,879,369. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $21.45 on Thursday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.97 and a 1 year high of $26.58. The company has a market capitalization of $2.62 billion, a P/E ratio of 13.66, a P/E/G ratio of 0.86 and a beta of 0.66. The business has a 50 day moving average price of $23.80 and a 200 day moving average price of $22.89.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.